Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HiCM-488
- Development stage
- Preclinical
- Lead developer
- Help Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
01
Overview
HiCM-488 is an allogeneic, off-the-shelf cell therapy product derived from induced pluripotent stem cells (iPSCs), developed by Help Therapeutics. It is specifically designed for the treatment of cardiovascular diseases. As an iPSC-based therapy, HiCM-488 is intended to function through tissue regeneration and replacement in the heart, rather than by targeting specific molecular pathways. The product is currently in the concept validation or preclinical stage of development, representing an early-stage approach to regenerative medicine for cardiac conditions.
Beyond the preview
Go deeper on HiCM-488.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HiCM-488.